Skip to main content
SpringerLink
Log in

Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease

  • Chapter
  • First Online:
Dyslipidemias in Kidney Disease

  • 773 Accesses

Abstract

Cardiovascular disease (CVD) is the leading cause of death in the Western world, including the United States and Europe. Chronic kidney disease is a common condition and is increasing globally; it is associated with an increased risk of CVD and chronic renal failure. In patients with chronic kidney disease, the relationship between dyslipidemia and CVD is less clear and potentially paradoxical. To understand the pharmacokinetic differences between the various statins, it is necessary to examine the structural differences, metabolic pathway, and risk of drug interactions. The objective of this chapter is to discuss the pharmacokinetic and pharmacodynamic properties of lipid-lowering drugs in patients with chronic kidney disease, those on dialysis, and patients following renal transplantation. This chapter will also discuss the safety, drug dosing, and drug interactions that are important in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kochanek KD, Xu JQ, Murphy SL, Miniño AM, Kung HC. Deaths: final data for 2009 [PDF-2M]. Nat Vital Stat Rep. 2011;60(3):2013.

    Google Scholar 

  2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.

    Article  PubMed  CAS  Google Scholar 

  3. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–421.

    Google Scholar 

  4. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant. 1996;11(1):63–9.

    Article  PubMed  CAS  Google Scholar 

  5. Coresh J, Longenecker JC, Miller III ER, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S24–30.

    PubMed  CAS  Google Scholar 

  6. Fellstrom B, Holdaas H, Jardine AG, Svensson MK, Gottlow M, Schmieder RE, et al. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin. 2009;25(1):271–85.

    Article  PubMed  Google Scholar 

  7. Jardine AG, Fellstrom B, Logan JO, Cole E, Nyberg G, Gronhagen-Riska C, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis. 2005;46(3):529–36.

    Article  PubMed  Google Scholar 

  8. U.S renal data system, USRDS 2006 annual data report: Atlas of end-stage Renal disease in the united states, national institutes of health, national institute of diabetes and digestive and kidney diseases, Bethesda, MD; 2008.2009. 2010.

    Google Scholar 

  9. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):S1–91.

    Google Scholar 

  10. Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin 1. 1976;11:1165–70.

    Article  PubMed  Google Scholar 

  11. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413–28.

    Article  PubMed  CAS  Google Scholar 

  12. Saito Y. Pitavastatin: an overview. Atheroscler Suppl. 2011;12(3):271–6.

    Article  PubMed  CAS  Google Scholar 

  13. Teresi RE, Planchon SM, Waite KA, Eng C. Regulation of the PTEN promoter by statins and SREBP. Hum Mol Genet. 2008;17(7):919–28.

    Article  PubMed  CAS  Google Scholar 

  14. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009;203(2):325–30.

    Article  PubMed  CAS  Google Scholar 

  15. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207–13.

    Article  PubMed  CAS  Google Scholar 

  16. Bianco AM, Zanin V, Marcuzzi A, Crovella S. Clarification of the pleiotropic effects of statins on mevalonate pathway and the feedback regulation of isoprenoids requires more comprehensive investigation. Cell Biochem Funct. 2012;30(2):176.

    Article  PubMed  CAS  Google Scholar 

  17. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58(11):719–31.

    PubMed  CAS  Google Scholar 

  18. Callahan III AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep. 2003;5(1):33–7.

    Article  PubMed  Google Scholar 

  19. Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J. 2002;144(6 Suppl):S27–32.

    Article  PubMed  CAS  Google Scholar 

  20. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32(5):403–25.

    Article  PubMed  CAS  Google Scholar 

  21. Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol. 2003;58(10):669–75.

    PubMed  CAS  Google Scholar 

  22. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54(5):472–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol. 1990;30(12):1128–35.

    Article  PubMed  CAS  Google Scholar 

  24. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol. 1992;32(7):630–8.

    Article  PubMed  CAS  Google Scholar 

  25. Radulovic LL, Cilla DD, Posvar EL, Sedman AJ, Whitfield LR. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol. 1995;35(10):990–4.

    Article  PubMed  CAS  Google Scholar 

  26. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):III50–7.

    PubMed  Google Scholar 

  27. Garcia MJ, Reinoso RF, Sanchez NA, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2003;25(6):457–81.

    Article  PubMed  CAS  Google Scholar 

  28. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47(7):463–74.

    Article  PubMed  CAS  Google Scholar 

  29. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105.

    Article  PubMed  CAS  Google Scholar 

  30. Hua WJ, Hua WX, Fang HJ. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther. 2012;30(5):e234–41.

    Article  PubMed  CAS  Google Scholar 

  31. Ma TK, Lam YY, Tan VP, Kiernan TJ, Yan BP. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther. 2010;125(2):249–59.

    Article  PubMed  CAS  Google Scholar 

  32. Tomita Y, Maeda K, Sugiyama Y. Clin Pharmacol Ther. 2013;94(1):37–51.

    Google Scholar 

  33. Yang SH, Choi JS, Choi DH. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology. 2011;88(1–2):1–9.

    PubMed  CAS  Google Scholar 

  34. Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother. 2009;43(12):2012–20.

    Article  PubMed  CAS  Google Scholar 

  35. Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012;13(5):579–94.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  36. Voora D, Ginsburg GS. Clinical application of cardiovascular pharmacogenetics. J Am Coll Cardiol. 2012;60(1):9–20.

    Article  PubMed  Google Scholar 

  37. Kajinami K, Masuya H, Hoshiba Y, Takeda K, Sato R, Okabayashi M, et al. Statin response and pharmacokinetics variants. Expert Opin Pharmacother. 2005;6(8):1291–7.

    Article  PubMed  CAS  Google Scholar 

  38. Gallelli L, Ferraro M, Spagnuolo V, Rende P, Mauro GF, De SG. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Drug Metabol Drug Interact. 2009;24(1):83–7.

    Article  PubMed  CAS  Google Scholar 

  39. Cilla Jr DD, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1996;36(7):604–9.

    Article  PubMed  CAS  Google Scholar 

  40. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs. 2007;67 Suppl 1:3–15.

    Article  PubMed  CAS  Google Scholar 

  41. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374–80.

    Article  PubMed  Google Scholar 

  42. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349–56.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Todd PA, Gemfibrozil WA. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs. 1988;36(3):314–39.

    Article  PubMed  CAS  Google Scholar 

  44. Benko S, Drabant S, Grezal G, Urmos I, Csorgo M, Klebovich I. Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. Arzneimittelforschung. 1997;47(8):913–6.

    PubMed  CAS  Google Scholar 

  45. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009;5(9):507–18.

    Article  PubMed  CAS  Google Scholar 

  46. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004;311(1):228–36.

    Article  PubMed  CAS  Google Scholar 

  47. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933–46.

    Article  PubMed  CAS  Google Scholar 

  48. McQuade CR, Griego J, Anderson J, Pai AB. Elevated serum creatinine levels associated with fenofibrate therapy. Am J Health Syst Pharm. 2008;65(2):138–41.

    Article  PubMed  CAS  Google Scholar 

  49. Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990;40(2):260–90.

    Article  PubMed  CAS  Google Scholar 

  50. Brown WV. Potential use of fenofibrate and other fibric acid derivatives in the clinic. Am J Med. 1987;83(5B):85–9.

    Article  PubMed  CAS  Google Scholar 

  51. Caldwell J. The biochemical pharmacology of fenofibrate. Cardiology. 1989;76 Suppl 1:33–41.

    Article  PubMed  Google Scholar 

  52. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375–84.

    Article  PubMed  CAS  Google Scholar 

  53. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291(4):451–9.

    Article  PubMed  CAS  Google Scholar 

  54. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–63.

    Article  PubMed  CAS  Google Scholar 

  55. Akioka K, Takahara S, Ichikawa S, Yoshimura N, Akiyama T, Ohshima S. Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan. World J Surg. 2005;29(2):249–56.

    Article  PubMed  Google Scholar 

  56. Kimak E, Ksiazek A, Baranowicz-Gaszczyk I, Solski J. Disturbed lipids, lipoproteins and triglyceride-rich lipoproteins as well as fasting and nonfasting non-high-density lipoprotein cholesterol in post-renal transplant patients. Ren Fail. 2007;29(6):705–12.

    Article  PubMed  CAS  Google Scholar 

  57. Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS. The Lipid-lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol. 2008;9:4.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Lewis D, Haynes R, Landray MJ. Lipids in chronic kidney disease. J Ren Care. 2010;36 Suppl 1:27–33.

    Article  PubMed  Google Scholar 

  59. Tomilina NA, Storozhakov GI, Gendlin GE, Badaeva SV, Zhidkova DA, Kim IG, et al. [Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney]. Ter Arkh. 2007;79(6):34–40.

    PubMed  CAS  Google Scholar 

  60. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16(2):529–38.

    Article  PubMed  Google Scholar 

  61. Rayner HC, Ross-Gilbertson VL, Walls J. The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy. Eur J Clin Invest. 1990;20(1):97–104.

    Article  PubMed  CAS  Google Scholar 

  62. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73(11):1303–9.

    Article  PubMed  CAS  Google Scholar 

  63. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41(3):565–70.

    Article  PubMed  CAS  Google Scholar 

  64. Olyaei A, Greer E, Delos SR, Rueda J. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. Clin J Am Soc Nephrol. 2011;6(3):664–78.

    Article  PubMed  CAS  Google Scholar 

  65. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40(1):67–73.

    Article  PubMed  CAS  Google Scholar 

  66. Buyukhatipoglu H, Sezen Y, Guntekin U, Kirhan I, Dag OF. Acute renal failure with the combined use of rosuvastatin and fenofibrate. Ren Fail. 2010;32(5):633–5.

    Article  PubMed  CAS  Google Scholar 

  67. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013;346:f880.

    Article  PubMed  Google Scholar 

  68. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid-lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51(15):1448–54.

    Article  PubMed  CAS  Google Scholar 

  69. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75(10):1487–96.

    PubMed  Google Scholar 

  70. Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease. XLVII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, June 25–28, 2010, Munich, Germany; 2010.

    Google Scholar 

  71. de Zeeuw D. Prospective evaluation of proteinuria and renal function in nondiabetic patients with progressive renal disease. 2010.

    Google Scholar 

  72. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;(2):CD007784.

    Google Scholar 

  73. Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20(2):146–52.

    Article  PubMed  CAS  Google Scholar 

  74. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  75. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43.

    Article  PubMed  CAS  Google Scholar 

  76. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55(24):2721–6.

    Article  PubMed  Google Scholar 

  77. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    Article  PubMed  CAS  Google Scholar 

  78. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;14:1395–407.

    Article  Google Scholar 

  79. Brown AS, Bakker-Arkema RG, Yellen L, Henley Jr RW, Guthrie R, Campbell CF, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 1998;32(3):665–72.

    Article  PubMed  CAS  Google Scholar 

  80. FDA. FDA: Limit Use of 80 mg Simvastatin. This article appears on FDA’s Consumer Updates page4, which features the latest on all FDA-regulated products June 8, 2011; 2011.

    Google Scholar 

  81. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288–95.

    Article  PubMed  CAS  Google Scholar 

  82. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C–94C.

    Article  PubMed  CAS  Google Scholar 

  83. Strain JD, Farver DK, Clem JR. A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy. Clin Pharmacol. 2010;2:95–104.

    PubMed Central  PubMed  CAS  Google Scholar 

  84. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105(5):978–80.

    Article  PubMed  Google Scholar 

  85. http://www.pbm.va.gov or http://vaww.pbm.va.gov. (Pravastatin, Rosuvastatin, Fluvastatin, Fluvastatin XL, Pitavastatin) VHA Pharmacy Benefits Management (PBM) Services, Medical Advisory Panel (MAP) and VISN Pharmacist Executives (VPEs). 2013.

  86. Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant. 2004;4(6):988–95.

    Article  PubMed  CAS  Google Scholar 

  87. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–25.

    Article  PubMed  CAS  Google Scholar 

  88. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–81.

    Article  PubMed  CAS  Google Scholar 

  89. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35(9):1096–107.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, Oregon Health and Sciences University, 3303 SW Bond Avenue, CH12C, Portland, OR, 97239, USA

    Ali Olyaei Pharm.D.

  2. Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI, USA

    Jessica Lassiter Pharm.D.

  3. Section of Nephrology, Advocate Christ Medical Center, University of Illinois at Chicago College of Medicine, Oak Lawn, IL, USA

    Edgar V. Lerma M.D., F.A.C.P., F.A.S.N., F.A.H.A., F.A.S.H., F.N.L.A., F.N.K.F.

Authors
  1. Ali Olyaei Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica Lassiter Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edgar V. Lerma M.D., F.A.C.P., F.A.S.N., F.A.H.A., F.A.S.H., F.N.L.A., F.N.K.F.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Olyaei Pharm.D. .

Editor information

Editors and Affiliations

  1. "C.I. Parhon" University Hospital, City, Iasi, Romania

    Adrian Covic

  2. Department of Medicine, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey

    Mehmet Kanbay

  3. Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA

    Edgar V. Lerma

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Olyaei, A., Lassiter, J., Lerma, E.V. (2014). Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease. In: Covic, A., Kanbay, M., Lerma, E. (eds) Dyslipidemias in Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0515-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0515-7_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0514-0

  • Online ISBN: 978-1-4939-0515-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation